File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Calcium-entry blockers and cardiovascular disease

TitleCalcium-entry blockers and cardiovascular disease
Authors
Issue Date1983
PublisherExcerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/
Citation
American Journal Of Cardiology, 1983, v. 52 n. 2, p. 99A-103A How to Cite?
AbstractThe beneficial effects of calcium-entry blockers in the treatment of ischemia in the heart and in other tissues can be explained by 1) relaxation of venous smooth muscle, in particular that of the splanchnic veins; 2) negative inotropic effect on the myocardial cells; 3) negative chronotropic effects on the heart; 4) inhibition of vasospastic episodes in coronary and other large arteries; 5) depression of myogenic activity and responsiveness to vasoconstrictor stimuli in precapillary resistance vessels; 6) inhibition of platelet aggregation; 7) possible increases in the deformability of hypoxic red blood cells; 8) protection of endothelial integrity and function; and 9) protection of the body cells, in particular myocardial cells, from prolonged exposure to anoxia and from massive entry of calcium during reperfusion. In the case of angina pectoris, the effects on the myocardial cells themselves, the decrease in preload and afterload, and the improvement of coronary perfusion combine to allow the heart to perform more work before an imbalance is reached between the metabolic demands of the myocardial cells and their blood supply. The increased myocardial performance may favor collateral circulation and withdrawal of the reflex load upon the heart, originating from the ischemic myocardium. The available calcium-entry blockers vary in their potency to affect the different components of the cardiovascular system.
Persistent Identifierhttp://hdl.handle.net/10722/170698
ISSN
2015 Impact Factor: 3.154
2015 SCImago Journal Rankings: 2.063
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorVanhoutte, PMen_US
dc.contributor.authorCohen, RAen_US
dc.date.accessioned2012-10-30T06:10:30Z-
dc.date.available2012-10-30T06:10:30Z-
dc.date.issued1983en_US
dc.identifier.citationAmerican Journal Of Cardiology, 1983, v. 52 n. 2, p. 99A-103Aen_US
dc.identifier.issn0002-9149en_US
dc.identifier.urihttp://hdl.handle.net/10722/170698-
dc.description.abstractThe beneficial effects of calcium-entry blockers in the treatment of ischemia in the heart and in other tissues can be explained by 1) relaxation of venous smooth muscle, in particular that of the splanchnic veins; 2) negative inotropic effect on the myocardial cells; 3) negative chronotropic effects on the heart; 4) inhibition of vasospastic episodes in coronary and other large arteries; 5) depression of myogenic activity and responsiveness to vasoconstrictor stimuli in precapillary resistance vessels; 6) inhibition of platelet aggregation; 7) possible increases in the deformability of hypoxic red blood cells; 8) protection of endothelial integrity and function; and 9) protection of the body cells, in particular myocardial cells, from prolonged exposure to anoxia and from massive entry of calcium during reperfusion. In the case of angina pectoris, the effects on the myocardial cells themselves, the decrease in preload and afterload, and the improvement of coronary perfusion combine to allow the heart to perform more work before an imbalance is reached between the metabolic demands of the myocardial cells and their blood supply. The increased myocardial performance may favor collateral circulation and withdrawal of the reflex load upon the heart, originating from the ischemic myocardium. The available calcium-entry blockers vary in their potency to affect the different components of the cardiovascular system.en_US
dc.languageengen_US
dc.publisherExcerpta Medica, Inc.. The Journal's web site is located at http://www.ajconline.org/en_US
dc.relation.ispartofAmerican Journal of Cardiologyen_US
dc.subject.meshBlood Viscosity - Drug Effectsen_US
dc.subject.meshCalcium Channel Blockers - Pharmacology - Therapeutic Useen_US
dc.subject.meshCoronary Disease - Drug Therapyen_US
dc.subject.meshCoronary Vasospasm - Prevention & Controlen_US
dc.subject.meshEndothelium - Drug Effectsen_US
dc.subject.meshHeart - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshModels, Biologicalen_US
dc.subject.meshMuscle, Smooth, Vascular - Drug Effectsen_US
dc.subject.meshMyocardial Contraction - Drug Effectsen_US
dc.subject.meshMyocardium - Cytologyen_US
dc.subject.meshPlatelet Aggregationen_US
dc.titleCalcium-entry blockers and cardiovascular diseaseen_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid6869263-
dc.identifier.scopuseid_2-s2.0-0020639665en_US
dc.identifier.volume52en_US
dc.identifier.issue2en_US
dc.identifier.spage99Aen_US
dc.identifier.epage103Aen_US
dc.identifier.isiWOS:A1983RB05400016-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.scopusauthoridCohen, RA=35562815800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats